Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + sertraline (Oizumi Hospital)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paroxetine + sertraline refers to a clinical treatment regimen and trial protocol (NCT01441076) evaluated by Oizumi Hospital for the management of major depressive disorder (MDD). The protocol investigates the efficacy of switching between these two selective serotonin reuptake inhibitors (SSRIs) in patients who fail to achieve an early clinical response (defined as a 20% reduction in MADRS scores) within the first two weeks of treatment. Both agents primarily function by inhibiting the serotonin transporter (SERT), thereby increasing synaptic serotonin levels. Paroxetine is also known for its mild muscarinic antagonism, while sertraline exhibits weak dopamine reuptake inhibition. This switching strategy aims to optimize therapeutic outcomes in non-responsive patients by leveraging potential differences in the pharmacodynamic profiles of these SSRIs.
- Brand names
- PaxilZoloft
- Other names
- SSRI switching protocol
02
Targets
SERT (Sodium-dependent serotonin transporter)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on paroxetine + sertraline (Oizumi Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + sertraline (Oizumi Hospital).